OKYO Pharma Limited
OKYO · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $8 | $6 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $7 | $7 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$7 | -$0 |
| Operating Expenses | $7 | $16 | $6 | $6 |
| Operating Income | -$7 | -$16 | -$13 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$8 | -$17 | -$13 | -$6 |
| Tax Expense | -$3 | $0 | -$0 | -$1 |
| Net Income | -$5 | -$17 | -$13 | -$5 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.001 | -0.6 | -0.36 |
| % Growth | -19,900% | 99.9% | -66.7% | – |
| EPS Diluted | -0.12 | -0.001 | -0.6 | -0.36 |
| Weighted Avg Shares Out | 39 | 29 | 22 | 15 |
| Weighted Avg Shares Out Dil | 39 | 29 | 22 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$16 | -$13 | -$6 |
| % Margin | – | – | – | – |